ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Olaparib is on this study

  • The record lists it as a treatment, written “AZD2281”.
  • Claude Opus 5.5 judged it tested: part of what the study tests. Nov 3, 2026, 5:17 AM UTC“Alone or with new partners by tumour mutation”
  • The role rule says the same.
  • So Olaparib's page lists this study under “Testing it”.
5 links0 made here, not in the record11 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govReplaced, or read an older version
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT02576444OLAParib COmbinationsJoseph Paul EderPhase 2 · terminatedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedMeSH filing re-derivedCONDITIONSNeoplasmsThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSOlaparibEntry “AZD2281”, read by our name rule›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedCapivasertibEntry “AZD5363”, read by our name rule›Nov 3 · Claude Opus 5.5 · BackgroundNov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · BackgroundTestedAdavosertibEntry “AZD1775”, read by our name rule›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCeralasertibEntry “AZD6738”, read by our name rule›Nov 3 · Claude Opus 5.5 · BackgroundNov 3 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partner

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
Nov 3OlaparibClaude Opus 5.5TestedCurrent
Nov 3CapivasertibClaude Opus 5.5BackgroundReplaced
Nov 3AdavosertibClaude Opus 5.5BackgroundCurrent
Nov 3CeralasertibClaude Opus 5.5BackgroundReplaced
Nov 3CapivasertibClaude Opus 5.5TestedCurrent
Nov 3CeralasertibClaude Opus 5.5Background · partnerCurrent
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 18OlaparibRule based · role ruleTestedAgrees
Nov 18CapivasertibRule based · role ruleBackgroundOverridden
Nov 18AdavosertibRule based · role ruleBackgroundAgrees
Nov 18CeralasertibRule based · role ruleBackgroundAgrees
As of nowNeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.